Nektar Therapeutics (NASDAQ:NKTR) Sets New 52-Week High – Time to Buy?

Nektar Therapeutics (NASDAQ:NKTR) shares reached a new 52-week high on Thursday . The company traded as high as $83.76 and last traded at $83.22, with a volume of 527547 shares changing hands. The stock had previously closed at $81.26.

Key Headlines Impacting Nektar Therapeutics

Here are the key news stories impacting Nektar Therapeutics this week:

• Positive Sentiment: Bullish readthrough on upcoming AA data — an investor/author predicts the upcoming REZOLVE‑AA (AA) dataset will be positive, which supports upside expectations for revenue and program valuation. Nektar Therapeutics Upcoming AA Data Prediction: Why I Think It Will Be Positive
• Negative Sentiment: Multiple class‑action filings and numerous law‑firm notices allege investor harm tied to disclosures from Feb 26, 2025–Dec 15, 2025; several firms are soliciting lead plaintiffs and remind investors the May 5, 2026 deadline to seek lead‑plaintiff status — this raises potential legal costs, settlement risk and short‑term volatility. Representative filings/alerts: ROSEN – Encourages Nektar Investors to Secure Counsel Glancy Prongay Wolke – Opportunity to Lead Securities Fraud Lawsuit Faruqi & Faruqi – Equity Alert Levi & Korsinsky – Investor Alert Pomerantz – Class Action Filed Bronstein Gewirtz & Grossman – Urges Investors to Act The Gross Law Firm – Shareholder Alert Bernstein Liebhard – Shareholder Alert

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on NKTR. Wall Street Zen raised shares of Nektar Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, April 11th. TD Cowen assumed coverage on shares of Nektar Therapeutics in a research report on Tuesday, March 17th. They set a “buy” rating on the stock. Oppenheimer reissued an “outperform” rating and set a $140.00 target price on shares of Nektar Therapeutics in a research report on Friday, March 13th. Wedbush started coverage on Nektar Therapeutics in a report on Tuesday, March 24th. They set a “neutral” rating and a $70.00 price target on the stock. Finally, Citigroup lifted their price target on Nektar Therapeutics from $102.00 to $123.00 and gave the stock a “buy” rating in a report on Monday, March 16th. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $128.13.

Nektar Therapeutics Stock Up 2.4%

The stock has a 50-day simple moving average of $70.31 and a 200-day simple moving average of $57.95. The firm has a market capitalization of $2.39 billion, a PE ratio of -8.16 and a beta of 1.16.

Nektar Therapeutics (NASDAQ:NKTR) last released its earnings results on Thursday, March 12th. The biopharmaceutical company reported ($1.78) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.69) by $0.91. Nektar Therapeutics had a negative return on equity of 386.16% and a negative net margin of 297.07%.The business had revenue of $21.81 million during the quarter, compared to the consensus estimate of $10.44 million. Equities analysts forecast that Nektar Therapeutics will post -0.72 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Howard W. Robin sold 423 shares of Nektar Therapeutics stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $73.00, for a total value of $30,879.00. Following the completion of the transaction, the chief executive officer owned 75,489 shares in the company, valued at $5,510,697. This trade represents a 0.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Jonathan Zalevsky sold 3,867 shares of Nektar Therapeutics stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $35.67, for a total transaction of $137,935.89. Following the completion of the transaction, the insider owned 21,354 shares of the company’s stock, valued at $761,697.18. The trade was a 15.33% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 4,470 shares of company stock valued at $181,955 in the last quarter. Corporate insiders own 5.25% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. BNP Paribas Financial Markets increased its position in shares of Nektar Therapeutics by 93.8% in the third quarter. BNP Paribas Financial Markets now owns 434 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 210 shares during the last quarter. Deutsche Bank AG increased its holdings in shares of Nektar Therapeutics by 0.8% in the 4th quarter. Deutsche Bank AG now owns 90,743 shares of the biopharmaceutical company’s stock worth $3,837,000 after buying an additional 743 shares during the last quarter. Bayforest Capital Ltd increased its holdings in shares of Nektar Therapeutics by 51.3% in the 4th quarter. Bayforest Capital Ltd now owns 2,541 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 862 shares during the last quarter. FNY Investment Advisers LLC increased its holdings in shares of Nektar Therapeutics by 70.6% in the 3rd quarter. FNY Investment Advisers LLC now owns 2,602 shares of the biopharmaceutical company’s stock worth $148,000 after buying an additional 1,077 shares during the last quarter. Finally, XTX Topco Ltd increased its holdings in shares of Nektar Therapeutics by 22.0% in the 4th quarter. XTX Topco Ltd now owns 7,196 shares of the biopharmaceutical company’s stock worth $304,000 after buying an additional 1,299 shares during the last quarter. 75.88% of the stock is currently owned by hedge funds and other institutional investors.

Nektar Therapeutics Company Profile

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.